Latest News and Updates | Cantargia

* (R) = Regulatory press releases

May 13, 2025

(R) Cantargia publishes interim report for the first quarter of 2025

May 12, 2025

Cantargia announces successful Phase 1 results: PK/PD data of subcutaneously administered CAN10 confirms every 4-week dosing choice in Phase 2

May 6, 2025

Cantargia’s announces publication of clinical data demonstrating potential of nadunolimab plus pembrolizumab in solid tumors

Apr 29, 2025

Invitation to the presentation of Cantargia’s interim report for Q1 2025

Apr 29, 2025

Cantargia announces selection of treatment resistant atopic dermatitis as second target indication for CAN10

Apr 28, 2025

Cantargia announces the publication of preclinical data highlighting nadunolimab's potential to counteract tumor-driven systemic immunosuppression

Apr 25, 2025

Cantargia presents promising preclinical results on anti-IL1RAP antibody-drug conjugate (ADC) at a major cancer conference

Apr 25, 2025

Cantargia presents association between nadunolimab and reduction of chemotherapy induced peripheral neuropathy (CIPN) at AACR

Apr 11, 2025

(R) Cantargia publishes Annual Report 2024

Apr 11, 2025

(R) Notice of annual general meeting in Cantargia AB (publ)

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye